Mutational activation of the KRAS oncogene is found in~ 95% of pancreatic ductal
adenocarcinoma (PDAC), the major form of pancreatic cancer. With substantial experimental …

Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A
hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene …

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, and no
targeted therapy is currently available. The aim of the present study was to investigate the …

Pancreatic cancer is a human malignancy with one of the highest mortality rates and little
progress has been achieved in its treatment in recent decades. Further improvement to the …

Despite significant advancements in the treatment of other cancers, pancreatic ductal
adenocarcinoma (PDAC) remains one of the world's deadliest cancers. More than 90% of …

Pancreatic cancer has a dismal prognosis due to late detection and lack of efficient
therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all …

Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most frequently mutated
oncogenes in solid tumors. More than 90% of pancreatic ductal adenocarcinoma (PDAC) …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers with a dismal
prognosis for the patient. This is due to limited diagnostic options for the early detection of …

Pancreatic ductal adenocarcinoma (PDAC) is almost universally fatal. The annual number of
deaths equals the number of newly diagnosed cases, despite maximal treatment. The …

Simple Summary Pancreatic ductal adenocarcinoma is one of the deadliest malignancies in
humans. Despite advances in systemic therapy, prognosis still remains poor. However …